Abstract:A series of ( E )-N-benzyl-1-(2, 4-dimethoxy-6-(4 methoxystyryl) phenyl) methanamine ( DMPM ) derivatives ( D1 - D25 ) were successfully synthesized in the form of hydrochloride, and characterized by spectroscopic techniques. The structure of D15 was further confirmed by X-ray single crystal diffraction, where D15 existed in the form of a dimer constructed by intermolecular hydrogen bonds between the active hydrogen of –NH 2 + − and Cl − , and the –CH=CH– in the molecule was identified as E configuration. Compounds were evaluated for their anti-cancer properties toward HepG2, Eac-109 and MDA-MB-231 cell lines in vitro. Meanwhile, bioactive compound's toxicity against L02 cell lines were also tested. Sixteen compounds ( D2, D5 - D8, D10, D13, D16 - D23 , and D25 ) exhibited significant cytotoxicity against tested cancer cells with IC 50 values ranging from 4.13 to 36.77 μM/L. Their toxicity toward normal human liver cells was lower than that of Cisplatin. Among them, D10, D20 and D25 showed more potent anti-cancer abilities than others. Especially, D20 manifested anti-cancer effects comparable to Cisplatin on all tested cancer cell lines. SAR revealed that –OCH 2 CH(CH 3 ) 2 or –O(CH 2 ) 3 CH 3 substitution (R 1 ) on the benzene ring of Pterostilbene is key factors in enhancing biological activities, while –OCH 3 , –Cl or –F substitution (R 2 ) on another benzene ring is beneficial for improving anti-cancer abilities, and –OCH 3 may be the most favorable modifying groups for enhancing skeleton's activities. Bioactive compounds displayed excellent inhibitory effects on COX-2 at nanomolar concentrations. D20 (IC 50 (COX-2) = 69.92 nm/L) was identified as the most promising COX-2 inhibitor, meanwhile, it also exhibited significant Topo I inhibitory ability at 20 μM/L. In addition, D20 effectively docked to COX-2 (PDB: 5KIR ) and Topo I protein (PDB: 1TBI ) with affinity of -9.0 and -5.7 kcal/mol, respectively. As a potential COX-2 and Topo I dual inhibitor, D20 induced ROS-mediate mitochondria dysfunction and altered the expression of apoptosis related proteins such as Bcl-2, Bax, Caspase3/9, and P53, leading to significant apoptosis in HepG2 cells. Moreover, D20 markedly up-regulated P21, reduced the level of CDK4 or Cyclin D1, and caused G1 phase arrest on HepG2 cancer cell lines.

Discovery of Novel Sulfonamide-Containing Aminophosphonate Derivatives As Selective COX-2 Inhibitors and Anti-Tumor Candidates.

Discovery of Novel Aminophosphonate Derivatives Containing Pyrazole Moiety As Potential Selective COX-2 Inhibitors.

Synthesis of Dihydropyrazole Sulphonamide Derivatives That Act As Anti-Cancer Agents Through COX-2 Inhibition

Dihydropyrazole Derivatives Containing Benzo Oxygen Heterocycle and Sulfonamide Moieties Selectively and Potently Inhibit COX-2: Design, Synthesis, and Anti-Colon Cancer Activity Evaluation.

Design, Synthesis and Biological Evaluation of Pyridine Acyl Sulfonamide Derivatives As Novel COX-2 Inhibitors

Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.

Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity

Discovery of Novel 1,3-Diaryl Pyrazolyl Ester Derivatives As COX-2 Inhibitory Candidates with Anti-Tumor Effect

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Design, Synthesis and Evaluation of Novel Diaryl-1,5-diazoles Derivatives Bearing Morpholine As Potent Dual COX-2/5-LOX Inhibitors and Antitumor Agents.

Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis

Discovery, synthesis, and anti-cancer evaluation of 10-Pterostilbene methylamine hydrochloride derivatives as potential COX-2 and Topo I dual inhibitors

AILDE Computer-Aided Discovery of Novel Ibuprofen-Coumarin Antitumor Lead Compounds Targeting Cyclooxygenase-2

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.

Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation

Design, Synthesis and Evaluation of Benzenesulfonamide-Substituted 1,5-Diarylpyrazoles Containing Phenylacetohydrazide Derivatives As Cox-1/Cox-2 Agents Against Solid Tumors

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives Possessing Benzotriazole Moiety As FAK Inhibitors with Anticancer Activity.

Discovery of Pyrazole-Thiophene Derivatives As Highly Potent, Orally Active Akt Inhibitors.

Novel Pyrazole Derivatives Bearing Carbonitrile and Substituted Thiazole Moiety for Selective COX‐2 Inhibition

New Thiazole Carboxamide Derivatives as COX Inhibitors: Design, Synthesis, Anticancer Screening, In Silico Molecular Docking, and ADME Profile Studies

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents